UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 10-Q
For the quarterly period ended March 31, 2025
OR
For the transition period from ____________to____________
Commission File No. 001-34220
__________________________
(Exact name of Registrant as Specified in its Charter)
__________________________
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | ||||
(Address of Principal Executive Offices and Zip Code)
(Registrant’s Telephone Number, Including Area Code): (803 ) 326-3900
_________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | ☒ | ||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ||||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Shares of Common Stock, par value $0.001 per share, outstanding as of May 2, 2025: 136,412,866 .
1
3D SYSTEMS CORPORATION
Form 10-Q
For the Quarter Ended March 31, 2025
Table of Contents
| PAGE NUMBER | |||||
2
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.
3D SYSTEMS CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited)
| (in thousands, except par value) | March 31, 2025 | December 31, 2024 | |||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
Accounts receivable, net of reserves — $ | |||||||||||
| Inventories | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
| Assets held for sale | |||||||||||
| Total current assets | |||||||||||
Property and equipment, net | |||||||||||
| Intangible assets, net | |||||||||||
| Goodwill | |||||||||||
| Operating lease right-of-use assets | |||||||||||
| Finance lease right-of-use assets | |||||||||||
| Long-term deferred income tax assets | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Current operating lease liabilities | $ | $ | |||||||||
| Accounts payable | |||||||||||
| Accrued and other liabilities | |||||||||||
| Customer deposits | |||||||||||
| Deferred revenue | |||||||||||
| Liabilities held for sale | |||||||||||
| Total current liabilities | |||||||||||
| Long-term debt, net of deferred financing costs | |||||||||||
| Long-term operating lease liabilities | |||||||||||
| Long-term deferred income tax liabilities | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities | |||||||||||
Commitments and contingencies (Note 12) | |||||||||||
| Redeemable non-controlling interest | |||||||||||
| Stockholders’ equity: | |||||||||||
Common stock, $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | ( | ( | |||||||||
| Accumulated other comprehensive loss | ( | ( | |||||||||
| Total stockholders’ equity | |||||||||||
| Total liabilities, redeemable non-controlling interest and stockholders’ equity | $ | $ | |||||||||
See accompanying notes to condensed consolidated financial statements.
3
3D SYSTEMS CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended | |||||||||||
| (in thousands, except per share amounts) | March 31, 2025 | March 31, 2024 | |||||||||
| Revenue: | |||||||||||
| Products | $ | $ | |||||||||
| Services | |||||||||||
| Total revenue | |||||||||||
| Cost of sales: | |||||||||||
| Products | |||||||||||
| Services | |||||||||||
| Total cost of sales | |||||||||||
| Gross profit | |||||||||||
| Operating expenses: | |||||||||||
| Selling, general and administrative | |||||||||||
| Research and development | |||||||||||
| Total operating expenses | |||||||||||
| Loss from operations | ( | ( | |||||||||
| Non-operating income (loss): | |||||||||||
| Foreign exchange gain, net | |||||||||||
Interest income | |||||||||||
Interest expense | ( | ( | |||||||||
| Other (loss) income, net | ( | ||||||||||
| Total non-operating income | |||||||||||
| Loss before income taxes | ( | ( | |||||||||
| Provision for income taxes | ( | ( | |||||||||
Loss on equity method investment, net of income taxes | ( | ( | |||||||||
| Net loss before redeemable non-controlling interest | ( | ( | |||||||||
Less: net loss attributable to redeemable non-controlling interest | ( | ||||||||||
| Net loss attributable to 3D Systems Corporation | $ | ( | $ | ( | |||||||
| Net loss per common share: | |||||||||||
| Basic | $ | ( | $ | ( | |||||||
| Diluted | $ | ( | $ | ( | |||||||
| Weighted average shares outstanding: | |||||||||||
| Basic | |||||||||||
| Diluted | |||||||||||
See accompanying notes to condensed consolidated financial statements.
4
3D SYSTEMS CORPORATION
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
| Three Month Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| Net loss before redeemable non-controlling interest | $ | ( | $ | ( | |||||||
| Other comprehensive income (loss), net of taxes: | |||||||||||
| Pension plan adjustments | ( | ||||||||||
| Foreign currency translation | ( | ||||||||||
| Total other comprehensive income (loss), net of taxes: | ( | ||||||||||
| Total comprehensive loss, net of taxes | ( | ( | |||||||||
| Less: comprehensive loss attributable to redeemable non-controlling interest | ( | ||||||||||
| Comprehensive loss attributable to 3D Systems Corporation | $ | ( | $ | ( | |||||||
See accompanying notes to condensed consolidated financial statements.
5
3D SYSTEMS CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| OPERATING ACTIVITIES | |||||||||||
| Net loss before redeemable non-controlling interest | $ | ( | $ | ( | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation and amortization | |||||||||||
| Accretion of debt discount | |||||||||||
| Stock-based compensation | |||||||||||
| Non-cash operating lease expense | |||||||||||
Provision for inventory obsolescence | |||||||||||
| Provision for bad debts | ( | ||||||||||
Loss on the disposition of businesses, property, equipment and other assets | |||||||||||
| Gain on debt extinguishment | ( | ||||||||||
| Provision for deferred income taxes and reserve adjustments | |||||||||||
Loss on equity method investment, net of taxes | |||||||||||
| Changes in operating accounts: | |||||||||||
| Accounts receivable | ( | ( | |||||||||
| Inventories | ( | ||||||||||
| Prepaid expenses and other current assets | ( | ( | |||||||||
| Accounts payable | ( | ( | |||||||||
| Deferred revenue and customer deposits | |||||||||||
| Accrued and other liabilities | ( | ( | |||||||||
| All other operating activities | ( | ( | |||||||||
| Net cash used in operating activities | ( | ( | |||||||||
INVESTING ACTIVITIES | |||||||||||
| Purchases of property and equipment | ( | ( | |||||||||
| Proceeds from sale of assets and businesses, net of cash sold | |||||||||||
| Acquisitions and other investments, net of cash acquired | ( | ||||||||||
| Other investing activities | ( | ||||||||||
| Net cash used in investing activities | ( | ( | |||||||||
| FINANCING ACTIVITIES | |||||||||||
| Repayment of borrowings/long-term debt | ( | ||||||||||
| Taxes paid related to net-share settlement of equity awards | ( | ( | |||||||||
| Other financing activities | ( | ( | |||||||||
| Net cash used in financing activities | ( | ( | |||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | ( | ||||||||||
| Net decrease in cash, cash equivalents and restricted cash | ( | ( | |||||||||
Cash, cash equivalents and restricted cash at the beginning of the year | |||||||||||
Cash, cash equivalents and restricted cash at the end of the period | $ | $ | |||||||||
Balances per Condensed Consolidated Balance Sheets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Restricted cash included in prepaid expenses and other current assets | |||||||||||
Restricted cash included in other assets (a) | |||||||||||
Total cash, cash equivalents and restricted cash | $ | $ | |||||||||
Continued on next page
See accompanying notes to condensed consolidated financial statements.
6
3D SYSTEMS CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Three Months Ended | |||||||||||
| Supplemental cash flow information | March 31, 2025 | March 31, 2024 | |||||||||
| Lease assets obtained in exchange for new lease liabilities | $ | $ | |||||||||
| Cash interest payments | |||||||||||
| Cash income tax payments, net | |||||||||||
Transfer of equipment from inventory to property and equipment, net (b) | |||||||||||
(a)Amounts included in restricted cash as of March 31, 2025 and March 31, 2024 primarily relate to guarantees in the form of a standby letter of credit as security for a long-term real estate lease. Refer to Note 12 for further information.
(b) Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.
See accompanying notes to condensed consolidated financial statements.
7
3D SYSTEMS CORPORATION
Condensed Consolidated Statements of Stockholders' Equity
Three Months Ended March 31, 2025 and 2024
(Unaudited)
| Common Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders' Equity | |||||||||||||||||||||||||||||||
| (in thousands, except par value) | Shares | Amounts | |||||||||||||||||||||||||||||||||
| December 31, 2024 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| Shares issued, vested and canceled under equity incentive plans | ( | ( | — | — | — | ( | |||||||||||||||||||||||||||||
| Shares withheld related to net-share settlement of equity awards | ( | — | ( | — | — | ( | |||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | |||||||||||||||||||||||||||||||
| Net loss attributable to 3D Systems Corp. | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||
| Pension plan adjustment | — | — | — | — | |||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | |||||||||||||||||||||||||||||||
| March 31, 2025 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| December 31, 2023 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| Shares issued, vested and canceled under equity incentive plans | — | — | — | — | — | ||||||||||||||||||||||||||||||
| Shares withheld related to net-share settlement of equity awards | ( | — | ( | — | — | ( | |||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | |||||||||||||||||||||||||||||||
| Net loss attributable to 3D Systems Corp. | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||
| Pension plan adjustment | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||
| Redeemable non-controlling interest redemption value in excess of carrying value | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||
| March 31, 2024 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
8
NOTE 1 - BASIS OF PRESENTATION
3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions (which includes dental, medical devices, personalized health services and regenerative medicine) and Industrial Solutions (which includes aerospace, defense, transportation and general manufacturing). We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.
Consolidated Entities
Summary of Significant Accounting Policies
There have been no significant changes to our accounting policies since those disclosed in the Company's 2024 Annual Report on Form 10-K.
Finance Leases
As of March 31, 2025 and December 31, 2024, short-term finance lease obligations of $1.5 10.3 million and $10.5 million, respectively, are included in Other liabilities on our Condensed Consolidated Balance Sheets.
Amortization of Intangible Assets
Amortization expense related to our intangible assets with finite lives was $0.6 million and $2.0 million for the three months ended March 31, 2025 and 2024, respectively.
9
Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, while permitted to be adopted on a retrospective basis. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Upon adoption, this ASU is expected to result in the inclusion of additional tax-related disclosures in the footnotes to our consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of the ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is currently in the process of evaluating the effects of this ASU on our consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments," related to induced conversions of convertible debt instruments. The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. This update is effective for annual periods beginning after December 15, 2025, including interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU permit an entity to apply the new guidance on either a prospective or retrospective basis. The Company is currently in the process of evaluating the effects of this ASU on our consolidated financial statements.
NOTE 2 - REVENUES
Contract Assets
In certain circumstances, contract assets are recorded to include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customers, and right to payment is subject to contractual performance obligations rather than subject only to the passage of time. Contract assets were $1.0 million and $0.3 million as of March 31, 2025 and December 31, 2024, respectively, and are included in Prepaid expenses and other current assets on the accompanying Condensed Consolidated Balance Sheets.
Contract Liabilities
Our contract liabilities consist of deferred revenue generally related to maintenance and service contracts, post-sale support and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. The current portion of deferred revenue is recorded within Accrued and other liabilities and the non-current portion of deferred revenue is recorded within Other long-term liabilities on our Condensed Consolidated Balance Sheets.
Our contract liabilities consisted of the following:
| (in thousands) | March 31, 2025 | December 31, 2024 | |||||||||
| Deferred revenue, current and customer deposits | $ | $ | |||||||||
| Deferred revenue, noncurrent | |||||||||||
| Total contract liabilities | $ | $ | |||||||||
During the three months ended March 31, 2025, the Company recognized $14.0 million of revenue related to the Company's contract liabilities at December 31, 2024. The change in contract liabilities from December 31, 2024 to March 31, 2025 was primarily due to the timing of cash receipts and sales of extended service contracts.
Collaborative Arrangements
The Company enters into collaborative arrangements with customers that provide for cost reimbursement of certain expenses and potential milestone payments.
10
The Company recognized $2.8 million and $2.0 million of products revenue, and $2.5 million and $2.1 million in product cost of sales, related to collaborative arrangements during the three months ended March 31, 2025 and March 31, 2024, respectively.
Remaining Performance Obligations
Remaining performance obligations represent the transaction price allocated to performance obligations that are unsatisfied as of the end of the period. As of March 31, 2025, the Company had $5.8 million of remaining performance obligations, primarily related to maintenance and service contracts, post-sale support and extended warranties. We expect approximately 90 % to be recognized as revenue within the next two years , and the remaining thereafter. We have excluded performance obligations with an original expected duration of one year or less.
Revenue Concentration
Revenue, by the geographic region in which a sale originated, was as follows:
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
Americas (a) | $ | $ | |||||||||
EMEA (b) | |||||||||||
| APAC | |||||||||||
| Total | $ | $ | |||||||||
(a) Includes total sales in the United States of $50.9 million and $59.9 million for the three months ended March 31, 2025 and 2024, respectively.
NOTE 3 - INVENTORIES
| (in thousands) | March 31, 2025 | December 31, 2024 | |||||||||
| Raw materials | $ | $ | |||||||||
| Work in process | |||||||||||
| Finished goods and parts | |||||||||||
| Total inventories | $ | $ | |||||||||
NOTE 4 - ASSETS HELD FOR SALE
In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments under the Asset Purchase Agreement and Business Transfer Agreement. The Company estimates it will record a pre-tax gain of approximately $125 million from the sale of Geomagic in the second quarter of 2025.
No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying condensed consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.
11
The Company determined that the associated assets and liabilities met the held for sale criteria. The following table summarizes the assets and liabilities of Geomagic:
| (in thousands) | March 31, 2025 | December 31, 2024 | |||||||||
| Assets | |||||||||||
Accounts receivable, net | $ | $ | |||||||||
| Prepaid expenses and other current assets | |||||||||||
| Total current assets held for sale | |||||||||||
Intangible assets, net | |||||||||||
| Other assets | |||||||||||
| Total assets held for sale | $ | $ | |||||||||
| Liabilities | |||||||||||
| Accounts payable | |||||||||||
| Accrued and other liabilities | |||||||||||
| Deferred revenue | |||||||||||
| Total current liabilities held for sale | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities held for sale | $ | $ | |||||||||
NOTE 5 - INVESTMENTS AND NOTE RECEIVABLE
The Company holds various investments in equity and note receivable that are reported in Other assets and Prepaid expenses and other assets on our Condensed Consolidated Balance Sheets. The following table summarizes our investment balances:
| (in thousands) | March 31, 2025 | December 31, 2024 | |||||||||
| Equity investments under the equity method of accounting | $ | $ | |||||||||
| Equity investments without readily determinable fair values | |||||||||||
| Total equity investments | $ | $ | |||||||||
During the three months ended March 31, 2025, the Company purchased additional shares of an equity method investment in Enhatch Inc. ("Enhatch") for $0.6 million. As of March 31, 2025, the Company owns approximately 72 % of Enhatch's outstanding common stock and approximately 41 % of Enhatch's outstanding voting stock.
Note Receivable - Related Party
In February 2023, we became a shareholder in a joint venture, National Additive Manufacturing Innovation ("NAMI") Joint Venture, formed with the Saudi Arabian Industrial Investments Company ("Dussur") for purposes of expanding the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa.
During December 2024, the Company entered into a short-term, non-interest bearing loan agreement with NAMI whereby NAMI borrowed $2.0 2.0
Additionally, during the three months ended March 31, 2025 and 2024, the Company entered into related party transactions for immaterial amounts with the companies that they also hold investments in. These transactions included immaterial purchases from and sales to these companies, which resulted in immaterial outstanding related party receivable and payable balances as of March 31, 2025 and 2024.
12
Other Asset
The Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, our EVP, Chief Technology officer of our Regenerative Medicine business and related party of the Company. The financing is recorded in Other assets on our Condensed Consolidated Balance Sheets as of March 31, 2025.
Variable Interest Entities ("VIEs")
The Company concluded that three of its investments are VIEs. These investments are not consolidated because we concluded that the Company is not the primary beneficiary. As of March 31, 2025, our maximum exposure to losses associated with the VIEs is limited to the $21.6 million carrying value of our investments in the VIEs, $3.0 million of which is included in Prepaid expenses and other current assets, with the remaining in Other assets on our Condensed Consolidated Balance Sheets. We have no other investments in unconsolidated entities that have been determined to be a VIE.
NOTE 6 - BORROWINGS
Convertible Notes
The Company previously issued 0 % Convertible Senior Notes due November 15, 2026 (the "Notes"), pursuant to an Indenture dated November 16, 2021 (the “Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee (the "Trustee").
The annual effective interest rate of the Notes is 0.594 % when including purchasers' discounts and commissions and offering expenses incurred by the Company. The Notes do not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on November 15, 2026, unless earlier redeemed, repurchased or converted in accordance with their terms.
The related principal, unamortized deferred issuance costs and carrying values were as follows:
| (in thousands) | March 31, 2025 | December 31, 2024 | |||||||||
Principal (a) | $ | $ | |||||||||
Unamortized deferred issuance costs | ( | ( | |||||||||
Carrying value | $ | $ | |||||||||
(a) The Notes have an initial conversion rate of 27.8364 shares of Common Stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture.
Prior to August 15, 2026, the Notes will only be convertible upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
The Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the Common Stock has been at least 130 % of the conversion price then in effect for a specified period of time.
The Company incurred $0.3 million and $0.4 million of debt issuance cost accretion for the three months ended March 31, 2025 and 2024, respectively.
In addition, in connection with the repurchase of a portion of the Notes in March 2024 (as further discussed below), the Company wrote off $1.8 million of debt issuance costs during the three months ended March 31, 2024. Debt issuance cost accretion of $1.0 million and $1.1 million is expected to be incurred for the remaining nine months of 2025 and the year ended December 31, 2026, respectively.
As of March 31, 2025, the Company was in compliance with all of the covenants included in the Indenture.
13
Debt Extinguishment
In March 2024, the Company repurchased $110.5 million of the Notes for $87.2 million, including transaction expenses. The repurchased Notes were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the Notes at a discount resulted in the recognition of a gain of $21.5 million, after transaction expenses and the write-off of related debt issuance costs, which is reported in Other (loss) income, net on the Company’s Condensed Consolidated Statement of Operations for the three months ended March 31, 2024.
NOTE 7 - STOCK-BASED COMPENSATION
2015 Incentive Plan
The Company is authorized to grant shares of restricted stock, restricted stock units (“RSU”), stock appreciation rights, cash incentive awards and options to purchase shares of Common Stock to employees and non-employee directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years.
dp polar Earnout
On October 4, 2022 the Company acquired dp polar. The acquisition agreement included an earnout arrangement for $2.2 million incremental to the acquisition purchase price, which would be settled via the issuance of 250 thousand shares of the Company's Common Stock. The dp polar earnout was settled subsequent to March 31, 2025 through the issuance of 250 thousand shares of the Company's Common Stock in April 2025 pursuant to the earnout agreement.
Stock-Based Compensation Activity and Expense
The following table shows the stock-based compensation expense recognized:
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
Stock-based compensation expense | $ | $ | |||||||||
Included in stock-based compensation expense recognized for the three months ended March 31, 2025 and 2024 are $0.5 million and $1.6 million, respectively, of accrued expense pertaining to annual incentive compensation for which settlement would ultimately occur using shares of Common Stock. There was no stock-based compensation expense relating to the dp polar earnout arrangement for the three months ended March 31, 2025 and the three months ended March 31, 2024 included $0.2 million of related expense.
As of March 31, 2025, there was $14.9 million of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 2 years.
NOTE 8 - INCOME TAXES
We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Accordingly, we have used a year-to-date methodology in determining the effective tax rate for the three months ended March 31, 2025 and 2024.
14
NOTE 9 - NET LOSS PER SHARE
Basic net loss per share is calculated by dividing net loss attributable to 3D Systems’ Common Stock stockholders by the weighted average number of shares of Common Stock outstanding during the applicable period. Diluted loss per share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such case when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date.
| Three Months Ended | |||||||||||
| (in thousands, except per share amounts) | March 31, 2025 | March 31, 2024 | |||||||||
| Numerator for basic and diluted net loss per share: | |||||||||||
| Net loss attributable to 3D Systems Corporation | $ | ( | $ | ( | |||||||
| Redeemable non-controlling interest redemption value in excess of carrying value | ( | ||||||||||
Net loss attributable to common stock shareholders | $ | ( | $ | ( | |||||||
| Denominator for net loss per share: | |||||||||||
Weighted average shares outstanding – basic and diluted(a), (b) | |||||||||||
| Net loss per share – basic and diluted | $ | ( | $ | ( | |||||||
(a) Equity awards are deemed anti-dilutive for the three months ended March 31, 2025 and 2024 because we reported a net loss for these periods.
(b) Includes 250 thousand shares of Common Stock related to the dp polar earnout arrangement issued in April 2025.
The following table presents the potentially dilutive shares that have been excluded from the computation of diluted net loss per share attributable to Common Stock stockholders because their effect is considered anti-dilutive.
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| Restricted stock and restricted stock units | |||||||||||
| Stock options | |||||||||||
| Total | |||||||||||
For the three months ended March 31, 2025, the table above excludes the following: (1) an estimate of 250 thousand shares that were contingently issuable under the dp polar earnout arrangement and were subsequently issued in April 2025 and (2) 146 thousand shares for the payment of accrued incentive compensation that is expected to be settled in shares. This share estimate is based on the liabilities recorded at March 31, 2025 for the fiscal year 2025 incentive compensation arrangement, divided by the Company's year-to date average share price of $3.42 per share.
For the three months ended March 31, 2024, the table above excludes the following: (1) an estimate of 166 thousand shares that are contingently issuable under the dp polar earnout arrangement and (2) an estimate of 324 thousand shares for the payment of accrued incentive compensation that is expected to be settled in shares. This share estimate is based on the liabilities recorded at March 31, 2024 for the fiscal year 2024 incentive compensation arrangement, divided by the Company's year-to-date average share price of $4.92 per share.
The Company previously issued 0 % Convertible Senior Notes due November 15, 2026, as discussed in Note 6. The Notes’ impact to diluted weighted average shares outstanding is required to be calculated using the if-converted method as prescribed in ASC 260. The Notes will increase the diluted weighted average shares outstanding when the average share price over a quarterly or annual reporting period is greater than $35.92 per share, the conversion price of the Notes. For the three months ended March 31, 2025 and 2024, the Notes were anti-dilutive on a stand-alone basis because the average share price during these periods did not exceed the conversion price, and because we reported a net loss for each of the respective periods.
15
NOTE 10 - ACCUMULATED OTHER COMPREHENSIVE LOSS
The changes in the balances of accumulated other comprehensive loss, net of tax, by component are as follows:
| Three Months Ended March 31, 2025 | |||||||||||||||||
| (in thousands) | Foreign currency translation adjustment | Defined benefit pension plan | Total | ||||||||||||||
| Balance at December 31, 2024 | $ | ( | $ | $ | ( | ||||||||||||
| Other comprehensive income | |||||||||||||||||
| Balance at March 31, 2025 | $ | ( | $ | $ | ( | ||||||||||||
| Three Months Ended March 31, 2024 | |||||||||||||||||
| (in thousands) | Foreign currency translation adjustment | Defined benefit pension plan | Total | ||||||||||||||
| Balance at December 31, 2023 | $ | ( | $ | $ | ( | ||||||||||||
| Other comprehensive loss | ( | ( | ( | ||||||||||||||
| Balance at March 31, 2024 | $ | ( | $ | $ | ( | ||||||||||||
NOTE 11 - SEGMENT INFORMATION
Our chief operating decision maker ("CODM"), who is our President and Chief Executive Officer, is responsible for reviewing segment performance and making decisions regarding resource allocation. Our CODM regularly reviews the results of our business through two reportable segments: Healthcare Solutions and Industrial Solutions, which are based on the industry verticals they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing.
The CODM evaluates each segment’s performance based on gross profit, which is also utilized in the annual budgeting and forecasting processes, as well as in quarterly reviews of budget-to-actual results and period-over-period variances. All internal segment reporting and discussions with the CODM are now based on segment gross profit. Prior period segment results have been revised to conform with current period presentation.
The CODM does not review disaggregated asset information on the basis of the Company's segments; therefore, such information is not presented.
16
Revenue, cost of sales and gross profit for each of our reportable segments were as follows:
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2025 | 2024 | |||||||||
| Revenue: | |||||||||||
| Healthcare Solutions | $ | $ | |||||||||
| Industrial Solutions | |||||||||||
| Total revenue | |||||||||||
| Cost of sales: | |||||||||||
| Healthcare Solutions | |||||||||||
| Industrial Solutions | |||||||||||
| Total cost of sales | |||||||||||
| Gross profit: | |||||||||||
| Healthcare Solutions | |||||||||||
| Industrial Solutions | |||||||||||
| Total gross profit | |||||||||||
| Selling, general and administrative | ( | ( | |||||||||
| Research and development | ( | ( | |||||||||
| Foreign exchange gain (loss), net | |||||||||||
| Interest income | |||||||||||
| Interest expense | ( | ( | |||||||||
| Other income (loss), net | ( | ||||||||||
Loss before income taxes | $ | ( | $ | ( | |||||||
Depreciation and amortization included in the measurement of gross profit by segment were as follows:
| Three Months Ended March 31, | |||||||||||
| (in thousands) | 2025 | 2024 | |||||||||
Depreciation and amortization: | |||||||||||
Healthcare Solutions | $ | $ | |||||||||
Industrial Solutions | $ | $ | |||||||||
NOTE 12 - COMMITMENTS AND CONTINGENCIES
The Company has certain purchase commitments under agreements with remaining terms in excess of one year primarily related to printer assemblies, inventory, capital expenditures, and software licenses. As of March 31, 2025, such purchase commitments totaled $14.4 million, with $8.1 million of the purchase obligations expected to be due within the next twelve months.
Indemnification
In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments that we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.
17
Other Commitments
Government Settlement
Beginning in October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce (“BIS”). In February 2023, the Company settled these matters with the U.S. Department of Justice (“DOJ”), DDTC and BIS. As a part of these settlement agreements, the Company agreed to pay $15.0 million in civil monetary penalties to these agencies, with an additional $10.0 million suspended penalty amount to be allocated to remedial compliance measures required by DDTC. The penalty amounts subject to payment were broken down as follows: DDTC, $10.0 million (payable in three installments over a three-year period); BIS, $2.8 million; and DOJ, $2.3 million.
During the three months ended March 31, 2025, we paid the final installment penalty of $3.0 million in accordance with the DDTC settlement agreement. The original $10.0 million suspended penalty has not been recognized as a liability, as it will be recognized as incurred for remedial compliance measures during the three-year term of the settlement agreement. The application of the Company’s spend on remedial compliance measures as a reduction to the original $10.0 million suspended penalty must be approved by DDTC, which approval will be sought on an annual basis in accordance with the terms of the settlement agreement. As of March 31, 2025, the approved suspended penalty balance remaining is $5.1 million. Any portion not expended for compliance measures at the end of the three-year term of the settlement agreement will be paid by the Company to DDTC.
Letter of Credit
On June 2, 2023, we issued $1.2 million of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has a maturity date of June 2025 and includes automatic one-year extensions, which are not to continue beyond July 1, 2033. The first automatic one-year extension occurred in June 2024, and the letter of credit now has a current maturity date of June 2025. As of March 31, 2025, the letter of credit was reduced to $0.8 million. We have not recorded any liability for this guarantee, as we believe that the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash and included in Other assets on our Condensed Consolidated Balance Sheets.
Litigation
SEC Investigation
On April 15, 2022, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, allegations that had been brought against the Company in a securities class action lawsuit that was brought against the Company in 2021 and settled in January 2024. The Company has subsequently received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The most recent SEC subpoena was received by the Company in August 2024, and requested additional documents and information relating to its continuing investigation of the Company. The Company completed its submission of this additional information to the SEC by the end of November 2024. The Company is continuing to cooperate with the SEC in connection with its formal investigation.
Termination of Volumetric Milestones Related to Potential Earnout Payments
Following the acquisition of Volumetric in 2021, the Company could have been required to pay up to $355.0 million of acquisition-related earnout payments to the former owners of Volumetric if the Company were to achieve seven non-financial, science-based milestones prior to either December 31, 2030 or December 31, 2035. Due to the loss of funding from the Company's key strategic partner for kidney and liver research and development efforts, the Company notified the former owners of Volumetric on February 24, 2024 that it was terminating the four milestones that related to those kidney and liver research and development efforts, as achievement was no longer financially viable. As a result of the termination of the four milestones, the Company's maximum liability for acquisition-related earnout payments was reduced to $175.0 million, which would have been payable if each of the three remaining non-financial, science-based milestones was achieved within the timeframes set forth in the Volumetric acquisition agreement.
On March 29, 2024, the former owners of Volumetric notified the Company that they were initiating dispute resolution under the provisions of the acquisition agreement in an effort to recover the $355.0 million. The parties did not reach a resolution during the 30 -day negotiation period following this notice and now have entered into non-binding mediation in accordance with the terms of the acquisition agreement.
18
On April 29, 2024, two key employees from Volumetric ("Volumetric Key Employees"), who were required to be employed at the time of achievement of each non-financial, science-based milestone outlined in the Volumetric acquisition agreement for each related acquisition earnout payment to become payable, resigned from their positions with the Company. As a result of the resignation of the Volumetric Key Employees, all parties to which the remaining three milestone-based earnout payments totaling $175.0 million were potentially payable were notified that such amount was no longer eligible to be earned. While the Volumetric Key Employees claim that their terminations were for good reason, which would preserve the rights to milestone-based earnout payments under the Volumetric acquisition agreement, the Company vigorously denies this claim. Presently, no lawsuit has been filed by the former owners of Volumetric to which milestone-based earnout payments were potentially payable, and there is no reasonable estimate or range of estimates of potential financial liability associated with this matter.
On August 21, 2024, the Company proposed a settlement of $1.8 million with the former shareholders and Volumetric Key Employees during mediation and this amount is recorded within Accrued and other liabilities on our Condensed Consolidated Balance Sheets as of March 31, 2025. The former shareholders have not responded to the settlement offer. On December 13, 2024, the Company received a Notice of Claim for Indemnification from VBI Stockholders’ Representative, LLC., which claims to be the successor Stockholders’ Representative under the acquisition agreement. The Notice repeated the former shareholders’ and Volumetric Key Employees' claims of breach. On January 10, 2025, the Company served a Notice of Objection which denied all liability. The delivery of this Notice of Objection triggered a 45-day negotiation period under the terms of the acquisition agreement. As of May 12, 2025, the Company has not heard anything further from the former shareholders and Volumetric Key Employees regarding this matter.
Intrepid Automation
On May 19, 2021, 3D Systems, Inc. initiated a lawsuit in the Superior Court of the State of California for the County of San Diego against five former employees and Intrepid Automation, Inc. (collectively, the “Intrepid Parties”) alleging theft of trade secrets, unfair competition, breach of contract, and related claims (“2021 Lawsuit”). In June 2021, this lawsuit was removed to the United States District Court for the Southern District of California. In September 2022, the Intrepid Parties filed counterclaims against 3D Systems, Inc. In September 2022, the Company filed a motion to dismiss these counterclaims; this motion was granted in part in May 2023. The Intrepid Parties filed amended counterclaims in May 2023 alleging theft of trade secrets, fraudulent inducement, breach of contract, unfair competition, and related claims; this amended complaint sought damages in excess of $20 million as well as injunctive relief. These counterclaims were partially dismissed in March 2024 in response to a second motion to dismiss filed by the Company. The parties filed motions for summary judgment in April and May 2024. In March 2025, the Court granted the Intrepid Parties’ motion, dismissing the Company’s claims against the Intrepid Parties, but denied the Company’s motion for summary judgment with respect to the counterclaims brought by the Intrepid Parties in the 2021 Lawsuit. On April 17, 2025, the Company filed motions asking the Court to reconsider its dismissal of the Company's claims or granting a partial final judgment so that the Company may appeal the dismissal.
On December 4, 2024, Intrepid Automation, Inc. (“Intrepid”) filed a lawsuit in the United States District Court for the Southern District of California against 3D Systems Corporation and 3D Systems, Inc. alleging infringement of U.S. patents 11,014,301 and 11,338,511 (“2024 Lawsuit”); this complaint seeks unspecified damages and injunctive relief.
The Company intends to defend itself vigorously against the 2024 Lawsuit and the counterclaims in the 2021 Lawsuit.
We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.
Contingencies
Warranty
Changes in accrued product warranty liability balance are summarized as follows:
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| Balance at beginning of period | $ | $ | |||||||||
| Settlements made | ( | ( | |||||||||
| Accruals for warranties issued | |||||||||||
| Balance at the end of period | $ | $ | |||||||||
19
NOTE 13 - FAIR VALUE MEASUREMENTS
Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:
•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.
•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
•Level 3 - One or more inputs are unobservable and significant.
Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Recurring Fair Value Measurements
The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:
Fair Value Measurement Using (a) | |||||||||||||||||||||||
| (in thousands) | Total Fair Value | Level 1 | Level 2 | Level 3 | |||||||||||||||||||
| March 31, 2025 | |||||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | |||||||||||||||||||
| December 31, 2024 | |||||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | |||||||||||||||||||
(a) There were no transfers among the levels within the fair value hierarchy during the three months ended March 31, 2025 or the year ended December 31, 2024.
Cash equivalents, including money market funds, are valued utilizing the market approach for measuring the fair value of financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of March 31, 2025 and December 31, 2024 because of the relatively short duration of these instruments.
Fair Value of Financial Instruments
The following table summarizes the carrying amount and fair value of our financial instruments:
| March 31, 2025 | December 31, 2024 | ||||||||||||||||||||||
| (in thousands) | Carrying Amount | Fair Value | Carrying Amount | Fair Value | |||||||||||||||||||
| Convertible notes | $ | $ | $ | $ | |||||||||||||||||||
NOTE 14 - RESTRUCTURING AND EXIT ACTIVITIES COSTS
2025 Restructuring Plans
In March 2025, the Company authorized the next phase of its multi-faceted cost savings and restructuring initiative (the “2025 Restructuring Plan”). The 2025 Restructuring Plan includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities.
The Company expects to incur approximately $12 million to $20 million in pre-tax restructuring and other related costs, primarily for severance and other termination benefits and facility exit costs by the end of the second fiscal quarter of 2026. The charges under the 2025 Restructuring Plan are expected to be primarily cash charges.
Additionally, in May 2025, the Company announced an incremental cost reduction initiative focused on labor force reductions in response to the uncertain macroeconomic environment that is expected to deliver significant cost savings in the second half of the year.
Restructuring and other related charges were as follows:
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 (a) | March 31, 2024 (b) | |||||||||
| Employee severance related | $ | $ | |||||||||
| Total restructuring charges | $ | $ | |||||||||
(a) Primarily relates to the 2025 Restructuring Plan
(b) Primarily relates to the 2023 Restructuring Plan
The restructuring and other related charges were primarily cash charges. These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| Cost of sales | $ | $ | |||||||||
| Selling, general, and administrative expenses | |||||||||||
| Research and development | |||||||||||
| Total | $ | $ | |||||||||
Restructuring and other related charges recorded in cost of sales by reportable segment were as follows:
| Three Months Ended | |||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | |||||||||
| Healthcare Solutions | $ | $ | |||||||||
| Industrial Solutions | |||||||||||
| Total | $ | $ | |||||||||
The activity in the restructuring accrual related to 2025 Restructuring Plan was as follows:
| (in thousands) | Balance as of December 31, 2024 | Costs Incurred | Paid / Settled | Balance as of March 31, 2025 | |||||||||||||||||||
| Employee severance related | $ | $ | $ | ( | $ | ||||||||||||||||||
| Total | $ | $ | $ | ( | $ | ||||||||||||||||||
2023 Restructuring Plan
20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of management and is intended to help the reader understand the results of operations and financial condition of the Company. Our MD&A should be read in conjunction with our MD&A and Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Annual Report on Form 10-K") and our Consolidated Condensed Financial Statements as of and for the three months ended March 31, 2024 included in this Form 10-Q.
Information Relating to Forward-Looking Statements
Certain statements contained in this MD&A may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed, or implied by, such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include without limitation:
•impact on our business as a result of macroeconomic events and other geopolitical risks, recession, supply chain disruptions, inflation, interest rates and foreign exchange volatility;
•our ability to deliver products that meet changing technology and customer needs;
•our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
•our ability to realize anticipated benefits for future dispositions;
•impact of future write-off or write-downs of goodwill and intangible assets;
•the concentration of revenue and credit risk exposure from our largest customer;
•our ability to acquire and enforce intellectual property rights and defend such rights against third-party claims;
•our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
•failure of our information technology infrastructure or inability to protect against cyber-attack;
•our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
•our ability to generate net cash flow from operations;
•our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
•our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
•fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
•our ability to efficiently conduct business outside the U.S.;
•our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
•our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
•product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
•our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
•our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
•disruption in our management information systems for inventory management, distribution, and other key functions;
21
•compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
•our ability to maintain our status as a responsible contractor under federal rules and regulations;
•changes in, or interpretation of, tax rules and regulations;
•our inability to use a Form S-3 Registration Statement; and
•the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2024 Annual Report on Form 10-K and this Form 10-Q.
Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.
Business Overview
3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.
The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.
Recent Developments and Updates Regarding Strategic Initiatives
2025 Restructuring Plan
In March 2025, the Company authorized the next phase of its multi-faceted cost savings and restructuring initiative (the “2025 Restructuring Plan”). The 2025 Restructuring Plan includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities.
The Company expects to incur approximately $12 million to $20 million in pre-tax restructuring and other related costs by the end of the second fiscal quarter of 2026. The charges under the 2025 Restructuring Plan are expected to be primarily cash charges.
Additionally, in May 2025, the Company announced an incremental cost reduction initiative focused on labor force reductions in response to the uncertain macroeconomic environment that is expected to deliver significant cost savings in the second half of the year.
22
Other Strategic Business Decisions and Cost Saving Initiatives
Geomagic Divestiture
In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments under the Asset Purchase Agreement and Business Transfer Agreement. The Company estimates it will record a pre-tax gain of $125.3 million from the sale of Geomagic in the second quarter of 2025.
No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying condensed consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.
Background
We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.
Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.
In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this MD&A, the price and mix effects relate to changes in revenue that are not able to be specifically attributed to changes in unit volume or changes in foreign exchange rates.
RESULTS OF OPERATIONS
Comparison of Results of Operations
| Three Months Ended | |||||||||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | Change | ||||||||||||||
| Revenue | $ | 94,540 | $ | 102,905 | $ | (8,365) | |||||||||||
| Cost of sales | 61,851 | 61,983 | (132) | ||||||||||||||
| Selling, general and administrative expenses ("SG&A") | 49,769 | 57,304 | (7,535) | ||||||||||||||
| Research and development expenses ("R&D") | 19,683 | 23,480 | (3,797) | ||||||||||||||
| Loss from operations | $ | (36,763) | $ | (39,862) | $ | 3,099 | |||||||||||
Revenue
The following table sets forth changes in our revenue for the three months ended March 31, 2025.
| (Dollars in thousands) | Products | Services | Total | ||||||||||||||||||||||||||||||||
Revenue - three months ended March 31, 2024 | $ | 64,051 | $ | 38,854 | $ | 102,905 | |||||||||||||||||||||||||||||
| Change in revenue: | |||||||||||||||||||||||||||||||||||
| Volume | (5,709) | (8.9) | % | 1,434 | 3.7 | % | (4,275) | (4.2) | % | ||||||||||||||||||||||||||
| Price/mix | (2,884) | (4.5) | % | — | — | % | (2,884) | (2.8) | % | ||||||||||||||||||||||||||
| Foreign currency translation | (735) | (1.1) | % | (471) | (1.2) | % | (1,206) | (1.2) | % | ||||||||||||||||||||||||||
| Net change | (9,328) | (14.6) | % | 963 | 2.5 | % | (8,365) | (8.1) | % | ||||||||||||||||||||||||||
Revenue - three months ended March 31, 2025 | $ | 54,723 | $ | 39,817 | $ | 94,540 | |||||||||||||||||||||||||||||
23
For the three months ended March 31, 2025, revenue decreased $8.4 million, or 8.1%, compared to the three months ended March 31, 2024. The decrease in revenue was primarily due to a decline in product revenue of $9.3 million driven by lower materials volume to customers in the dental, service bureaus, and jewelry markets and unfavorable price/mix which were partially offset by an increase in revenue from hardware systems. The decline in product revenue was partially offset by a $1.0 million increase in service revenue due to higher volume.
Cost of sales and gross profit
For the three months ended March 31, 2025, cost of sales remained relatively flat at $61.9 million compared to $62.0 million for the three months ended March 31, 2024. Declines related to lower sales volumes and a decrease in the provision for inventory obsolescence were mostly offset by unfavorable price/mix.
For the three months ended March 31, 2025, gross profit decreased $8.2 million, or 20.1%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to a combination of lower sales volumes and price/mix headwinds.
Selling, general and administrative expenses
For the three months ended March 31, 2025, selling, general and administrative expenses ("SG&A") decreased $7.5 million, or 13.1%, compared to the three months ended March 31, 2024. The year-over-year decline in SG&A was primarily due to:
•$5.7 million decrease in third-party service provider and consulting costs due to the increased cost to complete our fiscal 2023 audit during three three months ended March 31, 2024;
•$1.2 million decrease in amortization expense related to intangible assets due to lower intangible asset balances which were reduced by prior-year impairment charges; and
•$0.6 million decrease in compensation and benefits expense primarily related to lower stock-based compensation expense due to the timing of awards which was partially offset by increased incentive compensation.
Research and development expenses
For the three months ended March 31, 2025, research and development expenses ("R&D") decreased $3.8 million, or 16.2%, compared to the three months ended March 31, 2024. The year-over-year decline in R&D was primarily due to:
•$3.5 million decrease in compensation and benefits expense and other R&D expenses primarily due to improved operating efficiency and cost reductions realized from our restructuring activities.
Segment Results
Segment Revenue | Segment Gross Profit | ||||||||||||||||||||||||||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | Change | March 31, 2025 | March 31, 2024 | Change | |||||||||||||||||||||||||||||
| Healthcare Solutions | $ | 41,316 | $ | 45,413 | $ | (4,097) | $ | 16,024 | $ | 16,982 | $ | (958) | |||||||||||||||||||||||
| Industrial Solutions | 53,224 | 57,492 | (4,268) | 16,665 | 23,940 | (7,275) | |||||||||||||||||||||||||||||
| Total Company | $ | 94,540 | $ | 102,905 | $ | (8,365) | $ | 32,689 | $ | 40,922 | $ | (8,233) | |||||||||||||||||||||||
Healthcare Solutions
Revenue
For the three months ended March 31, 2025, Healthcare Solutions revenue decreased $4.1 million, or 9.0%, compared to the three months ended March 31, 2024. The decrease in revenue was primarily due to a decline in product revenue of $6.1 million which was partially offset by an increase in service revenue of $2.0 million. The decline in product revenue was primarily due to lower sales in the dental market, including lower materials volume with a key customer. Service revenue increased due to growth in personalized healthcare solutions and parts manufacturing revenue.
Gross profit
For the three months ended March 31, 2025, Healthcare Solutions gross profit decreased $1.0 million, or 5.6%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to lower sales volumes.
24
Industrial Solutions
Revenue
For the three months ended March 31, 2025, Industrial Solutions revenue decreased $4.3 million, or 7.4%, compared to the three months ended March 31, 2024. The decrease in revenue related to lower product and service revenue of $3.3 million and $1.0 million, respectively. The decline in product revenue was driven by lower materials sales to customers in the service bureaus and jewelry markets. The decline in service revenue was primarily due to decreases in hardware services and parts manufacturing revenue.
Gross profit
For the three months ended March 31, 2025, Industrial Solutions gross profit decreased $7.3 million, or 30.4%, compared to the three months ended March 31, 2024. The decrease in gross profit was primarily due to unfavorable price and mix and lower sales volumes.
Non-operating income (expense)
The following table sets forth the components of non-operating income:
| Three Months Ended | ||||||||||||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | Change | |||||||||||||||||
| Foreign exchange gain, net | $ | 1,139 | $ | 1,909 | $ | (770) | ||||||||||||||
| Interest income | 953 | 2,798 | (1,845) | |||||||||||||||||
| Interest expense | (581) | (714) | 133 | |||||||||||||||||
| Other (loss) income, net | (160) | 21,386 | (21,546) | |||||||||||||||||
| Total non-operating income | $ | 1,351 | $ | 25,379 | $ | (24,028) | ||||||||||||||
Foreign exchange gain, net
Foreign exchange gain, net decreased by $0.8 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, primarily due to realized and unrealized gains related to our foreign operations.
Interest income
Interest income decreased $1.8 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, due to the Company's lower cash and cash equivalent balances.
Interest expense
Interest expense decreased $0.1 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024, due to lower debt issuance cost amortization on lower debt balances resulting from the repurchase of debt in the prior year.
Other (loss) income, net
Other (loss) income, net, decreased $21.5 million for the three months March 31, 2025 as compared to the three months ended March 31, 2024, primarily due to a gain on the repurchase of debt in the three months ended March 31, 2024.
Income Taxes
For the three months ended March 31, 2025 and 2024, the Company’s effective tax rate was (1.9)% and (9.5)%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three months ended March 31, 2025 and 2024 were primarily driven by the recognition of a full deferred tax asset valuation allowance in various jurisdictions.
25
Liquidity and Capital Resources
The following table sets forth the Company's operating working capital at March 31, 2025 and December 31, 2024.
| Change | |||||||||||||||||||||||
| (in thousands) | March 31, 2025 | December 31, 2024 | $ | % | |||||||||||||||||||
| Cash and cash equivalents | $ | 135,040 | $ | 171,324 | $ | (36,284) | (21.2) | % | |||||||||||||||
| Accounts receivable, net | 104,691 | 101,471 | 3,220 | 3.2 | % | ||||||||||||||||||
| Inventories | 120,045 | 118,530 | 1,515 | 1.3 | % | ||||||||||||||||||
| 359,776 | 391,325 | (31,549) | (8.1) | % | |||||||||||||||||||
| Less: | |||||||||||||||||||||||
| Current operating lease liabilities | 11,775 | 9,514 | 2,261 | 23.8 | % | ||||||||||||||||||
| Accounts payable | 39,767 | 41,833 | (2,066) | (4.9) | % | ||||||||||||||||||
| Accrued and other liabilities | 44,310 | 45,488 | (1,178) | (2.6) | % | ||||||||||||||||||
| 95,852 | 96,835 | (983) | (1.0) | % | |||||||||||||||||||
| Operating working capital | $ | 263,924 | $ | 294,490 | $ | (30,566) | (10.4) | % | |||||||||||||||
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments, acquisitions and divestitures.
At March 31, 2025, cash and cash equivalents totaled $135.0 million and decreased $36.3 million since December 31, 2024. This decrease resulted primarily from cash used in operations of $33.8 million and capital expenditures of $2.8 million.
Cash held outside the U.S. at March 31, 2025 was $58.2 million, or 43.1% of total cash and cash equivalents, compared to $63.8 million, or 37.3% of total cash and cash equivalents, at December 31, 2024. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.
26
Cash Flow
The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. We expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity, equity-linked, and/or debt securities, subject to market conditions, will be available and sufficient to meet our anticipated cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:
| Three Months Ended | ||||||||||||||||||||
| (in thousands) | March 31, 2025 | March 31, 2024 | Dollar Change | |||||||||||||||||
| Cash flow used in operating activities | $ | (33,786) | $ | (25,545) | $ | (8,241) | ||||||||||||||
| Cash flow used in investing activities | (3,412) | (3,187) | (225) | |||||||||||||||||
| Cash flow used in financing activities | (649) | (89,187) | 88,538 | |||||||||||||||||
Operating Activities
Cash flows used in operating activities were $33.8 million during the three months ended March 31, 2025, an increase of $8.2 million, as compared to the three months ended March 31, 2024. The year-over-year change in operating cash flows was primarily attributable to the following factors:
•Year-over-year decrease of $6.5 million in operating cash flows from net earnings, net of non-cash items.
•The aggregate changes in trade accounts receivable, inventory, and trade accounts payable used $5.9 million of cash during the three months ended March 31, 2025 as compared to using $11.1 million during the prior year comparable period. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.
•The aggregate change in prepaid expenses, other assets, accrued expenses, and other liabilities used $7.8 million in the three months ended March 31, 2025 as compared to using $0.9 million in the comparable period in the prior year comparable period. The year-over-year changes were driven by the timing of accruals and payments and tax-related amounts.
Investing Activities
Net cash used in investing activities was $3.4 million during the three months ended March 31, 2025, a decrease of $0.2 million, as compared to the three months ended March 31, 2024, driven primarily by a decrease in purchases of property and equipment of $0.4 million, which was partially offset by an increase in our Enhatch investment of $0.6 million.
Financing Activities
Net cash used in financing activities was $0.6 million during the three months ended March 31, 2025, a decrease of $88.5 million, as compared to the three months ended March 31, 2024, driven primarily by repayments of long-term debt of $87.2 million and a decrease in taxes paid related to net-share settlement of equity awards of $1.4 million in the prior year period.
Material Cash Requirements
The Company's material cash requirements consist of the following contractual and other obligations:
Indebtedness
At March 31, 2025, we had $214.4 million of outstanding 0% convertible notes which mature in November of 2026. Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or strategic opportunities, which could result in higher financing costs.
27
Purchase Commitments
We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to printer assemblies, inventory, capital expenditures, and software licenses. As of March 31, 2025, such purchase commitments totaled $14.4 million, with approximately $8.1 million, expected to be due within the next twelve months.
Leases
The Company had operating and financing lease obligations (inclusive of interest) of $98.0 million at March 31, 2025, primarily related to real estate and equipment leases, of which approximately $18.2 million in payments are expected over the next twelve months.
Sources of Funding to Satisfy Material Cash Requirements
The Company believes that it has the financial resources needed to meet its anticipated cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.
Other Contractual Commitments
Indemnification
In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.
Critical Accounting Estimates
Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
Goodwill & other long-lived assets, including intangible assets
Long-lived assets, including intangible assets
We review long-lived assets (or asset groups), including intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset (or asset group) may not be recoverable. We assess the recoverability of the carrying value of assets (or asset groups) held for use based upon a review of undiscounted projected cash flows. Impairment losses, where identified, are measured as the excess of the carrying value of a long-lived asset (or asset group) over its estimated fair value, as determined using discounted projected cash flows. Our estimation of discounted projected cash flows requires us to make certain assumptions, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates.
28
Goodwill
Goodwill represents the amount by which the purchase price paid to consummate a business combination exceeds the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in the business combination. Goodwill is required to be assigned to a reporting unit for purposes of subsequent measurement and, as of March 31, 2025 and December 31, 2024, all of our reported goodwill was assigned to our Healthcare reporting unit.
We assess goodwill for impairment at least annually and, between annual impairment assessments, when circumstances indicate that there is a likelihood of greater than 50% that the carrying value of a reporting unit, inclusive of any assigned goodwill, exceeds the reporting unit’s fair value. On a forward-looking basis, such circumstances may include (1) a significant and sustained decrease in the trading price of our common stock that may suggest that the fair value of the Company and, accordingly, the fair value of our Healthcare reporting unit has declined, (2) a significant adverse change in the business climate for our Healthcare reporting unit, (3) a significant adverse change in the performance of our Healthcare reporting unit and/or (4) a decision to dispose of a significant portion of our Healthcare reporting unit.
When required to be performed, a quantitative goodwill impairment test compares the carrying value of a reporting unit to its fair value, and a goodwill impairment charge results when the reporting unit’s carrying value exceeds its fair value. The performance of a quantitative goodwill impairment test requires management to apply significant estimates and judgment – particularly to (1) estimate the fair value of the Company and each of our reporting units and (2) determine the carrying value of each of our reporting units, since we do not maintain separate balance sheets for our reporting units.
We estimate the fair value of our reporting units based primarily upon discounted cash flow projections for their underlying operations, which requires us to make significant assumptions regarding estimated cash flows, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates. We develop these assumptions based on the market risks unique to each reporting unit. In addition to the use of discounted cash flow projections, when appropriate, our estimates of the fair values of our reporting units include the results of applying the guideline company valuation method, which is a market approach. The application of the guideline company valuation method requires us to make judgments regarding (1) the appropriate set of comparable publicly traded guideline peer companies for which observable market multiples should be considered and (2) the appropriate multiple(s) to select from the range of multiples that may be observed for those guideline companies. We separately use reasonable and consistent allocation methodologies and approaches to allocate asset and liability balances to our reporting units when an account balance is not directly attributable to a specific reporting unit.
The remaining goodwill assigned to our Healthcare reporting unit could become subject to impairment upon any decrease in the estimated fair value of the Healthcare reporting unit or any increase in the estimated carrying value of the Healthcare reporting unit. Accordingly, over time, the key estimates, assumptions, and judgments that were used to estimate the fair value of our Healthcare reporting unit may change due to factors such as changes in market conditions and/or the actual performance of our Healthcare reporting unit. Similarly, over time, the carrying value of our Healthcare reporting unit could increase due to factors such as capital expenditures and/or the composition of the assets and liabilities of the Company and the underlying process and estimates required to allocate assets and liabilities that are not directly attributable to a specific reporting unit between/amongst our reporting units. Any unfavorable changes to the key estimates, assumptions, judgments or inputs utilized in our most recent quantitative goodwill impairment test – either on an individual basis or in the aggregate – could result in the recognition of impairment charges in the future.
There have been no material changes to our critical accounting estimates described in our 2024 Annual Report on Form 10-K.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
For a discussion of market risks at December 31, 2024, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2024 Annual Report on Form 10-K. During the three months ended March 31, 2025, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2024.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of March 31, 2025, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of March 31, 2025 due to the material weaknesses discussed in our 2024 Annual Report on Form 10-K.
29
Changes in Internal Control Over Financial Reporting
We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described in our 2024 Annual Report on Form 10-K. Related to these efforts was the development of a remediation plan to specifically address processes and activities intended to rectify the issues identified as part of the material weaknesses. These plans include, but are not limited to, increased training, enhanced documentation associated with existing policies, and talent enhancements designed to specifically address the identified weaknesses. Aside from these activities, the results of which continue to be evaluated, there were no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
The information relating to legal proceedings set forth under the header “Litigation” in Note 12 to the condensed consolidated financial statements as of and for the three months ended March 31, 2025 included in this Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors
Information regarding risk factors appears in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward Looking Statements," in Part I - Item 2 of this Form 10-Q and in "Risk Factors" in Part I - Item 1A of our 2024 Annual Report on Form 10-K. Except as set forth below, there were no material changes during the three months ended March 31, 2025 to the risk factors reported in our 2024 Annual Report on Form 10-K.
Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business and results of operations.
The U.S. has instituted or proposed changes in trade policies that include the imposition of higher tariffs on imports into the U.S. affecting trade between the U.S. and other countries where we conduct our business, such as China and certain European countries. The new tariffs and other changes in U.S. trade policy have and could continue to trigger retaliatory actions by affected countries, and foreign governments have imposed or are considering imposing trade sanctions on certain U.S. goods. Such actions have the potential to adversely impact the U.S. economy, our industry and the global demand for certain products, and as a result, could have a negative impact on our business, financial condition and results of operations.
Additionally, if the U.S. continues to affect changes to U.S. trade policy and impose such tariffs, this may cause supply chain disruptions and could further increase our costs. We may increase our sales prices in order to pass these increased costs to our customers, and our customers may, in turn, reduce their orders from us, which could negatively affect our business, profitability and operating results. While we are closely monitoring these developments and evaluating strategies to mitigate potential impacts, we may not be able to successfully mitigate the adverse impacts of these actions on our business and results of operations on a timely basis or at all.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuance of Unregistered Securities and Issuer Purchases of Equity Securities
Issuances of Unregistered Securities
None.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities in the open market during the three months ended March 31, 2025; however, shares of Common Stock were surrendered to us for payment of tax withholding obligations in connection with the vesting of restricted stock awards and units pursuant to our 2015 Incentive Stock Plan.
30
Total number of shares (or units) purchased (a) | Average price paid per share (or unit) (b) | ||||||||||
| January 1, 2025 - January 31, 2025 | — | $ | — | ||||||||
| February 1, 2025 - February 28, 2025 | 12,597 | 4.53 | |||||||||
| March 1, 2025 - March 31, 2025 | 83,165 | 2.74 | |||||||||
| Total | 95,762 | $ | 2.98 | ||||||||
a.Represents shares of Common Stock surrendered to us for payment of tax withholding obligations in connection with the vesting of restricted stock awards and units.
b.The average price paid reflects the average market value of shares withheld for tax purposes.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Director and Officer Trading Arrangements
During the fiscal quarter ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted terminated
31
Item 6. Exhibits
(a) | Exhibits | ||||
| The following exhibits are included as part of this filing and incorporated herein by this reference: | |||||
| 3.1 | Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-B filed on August 16, 1993, and the amendment thereto, filed on Form 8-B/A on February 4, 1994.) | ||||
| 3.2 | Amendment to Certificate of Incorporation filed on May 23, 1995. (Incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-2/A, filed on May 25, 1995.) | ||||
| 3.3 | |||||
| 3.4 | |||||
| 3.5 | |||||
| 3.6 | |||||
| 3.7 | |||||
| 4.1 | |||||
| 4.2 | |||||
| 4.3 | |||||
| 31.1† | |||||
| 31.2† | |||||
| 32.1† | |||||
| 32.2† | |||||
| 101.INS† | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because the its XBRL tags are embedded within the Inline XBRL document | ||||
| 101.SCH† | Inline XBRL Taxonomy Extension Scheme Document | ||||
| 101.CAL† | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF† | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB† | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE† | XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File - this data file does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document | ||||
† Exhibits filed herein. All exhibits not so designated are incorporated by reference to a prior filing, as indicated.
32
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| 3D SYSTEMS CORPORATION: | ||||||||
| Date: May 12, 2025 | By | /s/ Jeffrey D. Creech | ||||||
| Jeffrey D. Creech | ||||||||
Executive Vice President, Chief Financial Officer | ||||||||
33